Akarin

Akarin Therapeutics is an early-stage biotechnology company focused on developing transformative small molecule therapies for neurodegenerative and lysosomal storage disorders. The company's primary research efforts center on the GBA1 pathway, which is a critical genetic driver of Parkinson's disease and the cause of Gaucher disease. By designing potent activators of the glucocerebrosidase enzyme, Akarin aims to restore cellular homeostasis and provide disease-modifying treatments for patients with high unmet needs. The leadership team consists of industry veterans with extensive experience in rare disease drug development and commercialization.